Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways

• Main Authors: Gang Wang (Author), Chao Ma (Author), Kai Chen (Author), Ziyi Wang (Author), Heng Qiu (Author), Delong Chen (Author), Jianbo He (Author), Cheng Zhang (Author), Ding Guo (Author), Boyong Lai (Author), Shuangxiao Zhang (Author), Linfeng Huang (Author), Fan Yang (Author), Jinbo Yuan (Author), Leilei Chen (Author), Wei He (Author), Jiake Xu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due to over-activation of osteoclasts. However, current drugs targeting osteoclast inhibition face various side effects, making natural compounds with great interest as alternative treatment options. Cycloastragenol...